Market research
HTBX Heat Biologics Inc.
NYSE USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 73M
- P/E ratio
- Not available
- Analyst target
- 11.38
- Dividend yield
- 0.0%
- Beta
- 0.3
Profile
Company facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US42237K4094
- Market cap
- 73M
- P/E ratio
- Not available
- Analyst target
- 11.38
- Dividend yield
- 0.0%
- Beta
- 0.3
About
About Heat Biologics Inc.
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HTBX discussion.
5 years, 4 months ago
Heat Biologics, Inc is currently in a long term downtrend where the price is trading 10.1% below its 200 day moving average.
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 40.4.
Heat Biologics, Inc's total revenue sank by 69.8% to $603K since the same quarter in the previous year.
Its net income has increased by 99.8% to $-7K since the same quarter in the previous year.
Finally, its free cash flow fell by 1626.2% to $-6M since the same quarter in the previous year.
Based on the above factors, Heat Biologics, Inc gets an overall score of 2/5.